Disc Medicine, Inc. Common Stock
IRONDisc Medicine, Inc. (IRON) is a clinical-stage biopharmaceutical company focused on developing therapies for serious and rare hematologic diseases. The company aims to address unmet medical needs through innovative drug discovery and development, with particular emphasis on conditions related to iron metabolism and anemia.
Company News
The FDA has delayed reviews of several drugs in the Trump administration's fast-track approval program (CNPV) due to safety and efficacy concerns. Disc Medicine's bitopertin for rare blood disorder, Sanofi's Tzield for type 1 diabetes, and Eli Lilly's orforglipron weight-loss pill have all experienced timeline extensions. Regulators cited issues ...
Disc Medicine reported promising results from its Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis patients, demonstrating substantial hematologic responses across different patient subgroups and transfusion statuses.
Bain Capital Life Sciences Investors completely sold its entire stake in Disc Medicine during Q3 2025, disposing of 583,500 shares worth approximately $30.90 million, signaling a potential shift in institutional sentiment towards the biotech company.
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential commercialization of bitopertin and fund research and development.
